Form 4: Bio-Rad Laboratories Director Steven Schwartz Reports Sale of Class A Common Stock

Director Steven Schwartz reported selling 320 shares of Bio-Rad Laboratories Class A common stock at $463.86 per share on May 3, 2023.

Summary

• On May 3, 2023, Steven Schwartz, a director at Bio-Rad Laboratories, sold 320 shares of Class A common stock at a price of $463.86 per share.
• Following the transaction, Schwartz directly owns 25,177 shares of Bio-Rad Class B common stock and 362,146 shares of Class A common stock.
• Schwartz also indirectly owns 12,949 shares of Class B common stock and 1,498.0335 shares of Class A common stock through his spouse.
• Additionally, Schwartz indirectly owns 4,060,054 shares of Class B common stock through Blue Raven Partners, L.P., where he is a limited and general partner.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a transaction by an insider. It doesn't inherently convey positive or negative sentiment; it's simply a report of a stock sale.

Industry Context

This filing is a routine disclosure of insider trading activity and doesn't necessarily reflect a broader trend in the biotechnology or diagnostics industry. It is common for executives and directors to periodically buy or sell shares of their company's stock.

Stakeholder Impact

• The sale of shares by a director could be perceived neutrally or slightly negatively by shareholders, depending on the context and the size of the transaction.
• However, this single transaction is unlikely to have a significant impact on other stakeholders such as employees, customers, suppliers, or creditors.

Key Dates